Resources
and Financial
Assistance

Lilly PatientOne strives to offer reliable and individualized treatment support for eligible patients prescribed a Lilly Oncology product whether they are insured, underinsured, or simply uninsured.

Co-pay Program

  • Lilly PatientOne Co-pay Program—patients pay no more than $25 per dose—to assist eligible patients with co-pay and coinsurance costs for prescribed Lilly Oncology products where available*

  • No income eligibility requirement

  • Provides an annual maximum patient benefit of $25,000

For more information, visit www.LillyPatientOne.com.

*This offer is invalid for patients whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program.

Insurance Expertise

  • Coding and billing information

  • Payment methodologies and allowables

  • Payer policy information

Reimbursement Assistance

  • Eligibility determination

  • Benefits investigation

  • Prior authorization assistance

  • Denied claims appeals information

Lilly Cares Foundation

The Lilly Cares Foundation, Inc, a separate nonprofit organization, provides free Lilly medications to qualifying patients. For more information about Lilly Cares, please visit LillyCares.com or call
1-800-545-6962.

For more information about Lilly PatientOne, call
1-866-4PatOne (1-866-472-8663),
Monday–Friday, 9 am–7 pm ET, or visit LillyPatientOne.com.

Other Helpful Resources

Advocacy organizations provide a range of resources that can be valuable to patients. Below are some of the largest national organizations, but it may also be useful to connect with local groups.

  • National Cancer Institute —
    Adult Soft Tissue Sarcoma

    The central website for the National Cancer Institute (NCI), the U.S. government’s principal agency for cancer research.

  • American Cancer Society

    Nationwide, community-based voluntary health organization dedicated to providing information to support patients and funding cancer research.

  • Sarcoma Alliance

    Non-profit organization dedicated to improving the lives of people affected by sarcoma.

  • Sarcoma Foundation of America

    Non-profit organization that advocates for sarcoma patients by funding research and increasing awareness about the disease.

ADDITIONAL LARTRUVO
MATERIALS

  • Download and print a short guide to treatment with LARTRUVO + doxorubicin.

  • Download and print important questions
    you may want to ask your doctor
    at your
    next visit.

INDICATION AND IMPORTANT SAFETY INFORMATION

EXPAND

WHO IS LARTRUVO FOR?

LARTRUVO (olaratumab) is a prescription medicine used with a type of chemotherapy called doxorubicin to treat adult patients with soft tissue sarcoma (STS) for whom doxorubicin is appropriate and who cannot be cured with radiation or surgery.

There is an ongoing study to confirm how LARTRUVO works in combination with doxorubicin.

IMPORTANT SAFETY INFORMATION FOR LARTRUVO

What is the most important information I should know about LARTRUVO?

  • Infusion reactions related to injecting LARTRUVO have occurred. Most of these reactions happened during or after the first or second LARTRUVO infusion. Signs and symptoms of infusion reactions include flushing, shortness of breath, severe trouble breathing, or fever/chills. In severe cases, severe low blood pressure, anaphylactic shock (a severe, potentially life-threatening allergic reaction), or cardiac arrest (abrupt loss of heart function) may occur. Tell your doctor if you have any of these symptoms. Your healthcare team will monitor you for these side effects. In the case of a severe infusion reaction, your LARTRUVO treatment will have to be immediately and permanently stopped.

  • LARTRUVO can harm your unborn baby. You should avoid getting pregnant, and use effective birth control while receiving LARTRUVO and for at least 3 months after stopping LARTRUVO.

What are the most common side effects of LARTRUVO?

  • The most common side effects reported in patients treated with LARTRUVO when given in combination with doxorubicin were nausea; tiredness or weakness; pain in the muscles, joints, and bones; sores and swelling of the mouth and digestive tract; hair loss; vomiting; diarrhea; decreased appetite; stomach pain; weakness, numbness, or pain in the hands and feet; and headache.

  • The most common changes to blood tests were low white blood cell count, low platelet count, high blood sugar, increased blood clotting time, low blood potassium level, and low blood phosphate level.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/safety/medwatch or call 1-800-FDA-1088.

What should I tell my doctor before receiving treatment with LARTRUVO?

Before you receive LARTRUVO, tell your doctor if you:

  • Are pregnant or may be pregnant. If you become pregnant during treatment, discuss this with your doctor.

  • Are breastfeeding: your doctor will tell you not to breastfeed during LARTRUVO treatment and for at least 3 months after stopping LARTRUVO.

Tell your doctor about all the medications you are taking, including prescription and over-the-counter medications.

LARTRUVO is available by prescription only.

Please see full Prescribing Information for additional information about LARTRUVO.

OR CON ISI 12JAN2017

WHO IS LARTRUVO FOR?

LARTRUVO (olaratumab) is a prescription medicine used with a type of chemotherapy called doxorubicin to treat adult patients with soft tissue sarcoma (STS) for whom doxorubicin is appropriate and who cannot be cured with radiation or surgery.

There is an ongoing study to confirm how LARTRUVO works in combination with doxorubicin.

IMPORTANT SAFETY INFORMATION FOR LARTRUVO

What is the most important information I should know about LARTRUVO?

  • Infusion reactions related to injecting LARTRUVO have occurred. Most of these reactions happened during or after the first or second LARTRUVO infusion. Signs and symptoms of infusion reactions include flushing, shortness of breath, severe trouble breathing, or fever/chills. In severe cases, severe low blood pressure, anaphylactic shock (a severe, potentially life-threatening allergic reaction), or cardiac arrest (abrupt loss of heart function) may occur. Tell your doctor if you have any of these symptoms. Your healthcare team will monitor you for these side effects. In the case of a severe infusion reaction, your LARTRUVO treatment will have to be immediately and permanently stopped.

  • LARTRUVO can harm your unborn baby. You should avoid getting pregnant, and use effective birth control while receiving LARTRUVO and for at least 3 months after stopping LARTRUVO.

What are the most common side effects of LARTRUVO?

  • The most common side effects reported in patients treated with LARTRUVO when given in combination with doxorubicin were nausea; tiredness or weakness; pain in the muscles, joints, and bones; sores and swelling of the mouth and digestive tract; hair loss; vomiting; diarrhea; decreased appetite; stomach pain; weakness, numbness, or pain in the hands and feet; and headache.

  • The most common changes to blood tests were low white blood cell count, low platelet count, high blood sugar, increased blood clotting time, low blood potassium level, and low blood phosphate level.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/safety/medwatch or call 1-800-FDA-1088.

What should I tell my doctor before receiving treatment with LARTRUVO?

Before you receive LARTRUVO, tell your doctor if you:

  • Are pregnant or may be pregnant. If you become pregnant during treatment, discuss this with your doctor.

  • Are breastfeeding: your doctor will tell you not to breastfeed during LARTRUVO treatment and for at least 3 months after stopping LARTRUVO.

Tell your doctor about all the medications you are taking, including prescription and over-the-counter medications.

LARTRUVO is available by prescription only.

Please see full Prescribing Information for additional information about LARTRUVO.

OR CON ISI 12JAN2017

X

You are now leaving the www.LARTRUVO.com website.

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC, does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC, is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.

  • Continue

  • Cancel

X

For US Healthcare Professionals

The information contained in www.LARTRUVO.com/hcp is technical in nature and intended for healthcare professionals in the United States only.

I'd like information for:

  • Healthcare Professionals

  • Patients and Caregivers